Upperton Opens New Development and GMP Manufacturing Facility
Upperton Pharma Solutions was joined by Sarah Gilbert, Professor and co-creator of the Oxford/AstraZeneca COVID-19 vaccine for the official opening of its new development and GMP manufacturing facility in Nottingham, UK.
UK-based contract development and manufacturing organization (CDMO) Upperton Pharma Solutions recently celebrated the official opening of a new 50,000 square foot development and GMP manufacturing facility in Nottingham.
Nikki Whitfield, CEO of Upperton Pharma Solutions, commented, “This celebration marks another milestone in our incredible growth journey as a business. We are looking forward to officially opening our doors to customers and offering a single site solution for development and GMP manufacturing.”
The new facility contains ten GMP manufacturing suites, cutting-edge quality control laboratories, and formulation development capabilities equipped with a pilot plant. The facility enables Upperton to offer customers early formulation development to clinical trial supplies from Phase 1 to Phase 3 and niche scale commercial manufacturing all on one site.
“It was a pleasure to join Upperton for the grand opening of their new facility”, said Sarah Gilbert, co-creator of the Oxford/AstraZeneca COVID-19 vaccine. “During the pandemic we saw the importance of academia and industry working closely together to deliver life-saving vaccines and treatments. Upperton’s expansion into this new site is a great example of the crucial role UK-based pharmaceutical organisations have to play in addressing global health challenges. I look forward to collaborating with Upperton in the future.”
The official opening marks another milestone for Upperton following the announcement and ongoing build of a new sterile facility on the same site, for the manufacturing of aseptic and terminally sterilized small-volume liquids for parenteral, ocular, and pulmonary delivery due for completion at the end of 2024.
